Appili Therapeutics Inc Class A
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Don Cilla
- Full Time Employees
- 7
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1344 Summer Street Halifax NS Canada B3H 0A8
- IPO Date
- Jun 25, 2019
- Website
- appilitherapeutics.com
- Similar Companies
- Business
- Appili Therapeutics, Inc. is a biopharmaceutical company, which engages in acquisition and development of novel treatments targeting unmet needs in infectious disease. It focuses on building and advancing a diverse portfolio of anti-infective programs such as LIKMEZ, ATI-1701 and ATI-1801. The company was founded on May 7, 2015 and is headquartered in Halifax, Canada.
Company News
Appili Therapeutics Announces Transfer to NEX
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027
Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program
Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
Appili Therapeutics to Exhibit at World Vaccine Congress Washington
Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
Appili Therapeutics to Attend BARDA Innovation Symposium 2025
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026
Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update